CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 29 enrolled
Drug / intervention
Lidocaine +1 moredrug
Likely dose
Lidocaine 3 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02217267
NCT02217267Phase 3Completed

Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain : A Pilot Study

Mahidol University·interventional·Posted Aug 15, 2014·Updated Nov 30, 2022

In Brief

A Phase 3 clinical trial evaluating Lidocaine and Placebo for Peripheral Neuropathy. Completed, enrolled 29 participants across 1 site.

Detailed Summary

The purpose of this study to evaluated Long term outcome after serial Lidocaine infusion when compared with placebo in peripheral neuropathic pain patients in acute stage (less than 6 months) at 3 months after first time of infusion

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesThailand
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 15, 2014
Enrollment StartAug 1, 2014
Primary CompletionDec 29, 2017
Study CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 11.9 years ago

Interventions

Lidocainedrug

Lidocaine 3 mg/kg dilute in Normal Saline to 50 ml intravenous infusion in 1 hour

Placebodrug